The Uromigos

Episode 290: ASCO GU 2024 Preview 17.01.2024 26:58 ↓

What to look out for in bladder, prostate and renal cancer at this year's meeting.

Episode 289: The Uromigos Paper of the Month - TALAPRO2 in Nature Medicine 15.01.2024 36:02 ↓

Karim Fizazi discusses the clinical and biomarker components of this data.

Episode 288: APCCC #3: Controversies around Radiotherapy 10.01.2024 36:29 ↓

Thomas Zilli discusses controversies around radiotherapy in prostate cancer.

Episode 287 APCCC: Early Discontinuation of Therapy in HSPC 04.01.2024 34:48 ↓

Silke Gillessen and Betrand Tombal discuss the questions which will address this issue in Lugano in March 2024.

Episode 286: APCCC Prostate Cancer Meeting Overview 03.01.2024 30:22 ↓

Silke Gillessen discusses this biannual meeting taking place in Lugano in March 2024.

Episode 285: Holiday Special: Renal Cancer in 2023 22.12.2023 26:02 ↓

Cristina Suarez discusses the year in review.

Episode 283: Holiday Special: Prostate Cancer in 2023 20.12.2023 34:34 ↓

Tanya Dorff discusses her favourite prostate cancer studies of the year.

Episode 282: Holiday Special: Bladder Cancer in 2023 13.12.2023 38:12 ↓

Kala Sridhar discusses all the key trials in 2023. She also reveals her favourite Xmas song.

Episode 281: The Uromigos Paper of the Month - Lu-177 with Pembrolizumab in Prostate Cancer 08.12.2023 25:23 ↓

Rahul Aggarwal describes his phase 1/2 study with only 1 cycle of Lu-177 in CRPC.

Episode 280: IKCS 2023 Overview 16.11.2023 35:24 ↓

Tian Zhang discusses this fabulous renal cancer meeting. Belzutifan is covered too.

An apology 13.11.2023 1:47 ↓

Tom and Brian apologise for the unacceptable words and images which were broadcast by hackers during the Uromigos livestream last week. We’re really sorry and will do everything we can to make sure it never happens again.

Episode 279: Management of IO-resistant RCC at #UromigosLive 2023 06.11.2023 1:00:37 ↓

Monty Pal, Toni Chouieri, and Tian Zhang join Tom and Brian to discuss CONTACT-03, TiNivo-2, IO-based therapy, and more. Recorded live at Uromigos Live & Unplugged 2023 in Nashville, TN.

Episode 278: Current and Future Status of Radioligand Therapy at #UromigosLive 2023 04.11.2023 39:31 ↓

Brian is joined by Neeraj Agarwal, Tanya Dorff, Rana McKay, and Michael Morris to review the state of radioligand therapy. The panel examines primary and secondary end points of VISION, current practice patterns, the right way to dose 177Lu-PSMA, PSMAfore, and more. Recorded live at Uromigos Live & Unplugged 2023 in Nashville, TN.

Episode 277: NMIBC Discussion at #UromigosLive 2023 04.11.2023 44:04 ↓

Tom is joined by Sam Chang, Sia Daneshmand, and Petros Grivas to discuss new therapies in non-muscle invasive bladder cancer, including those for BCG-refractory NMIBC and the cretostimogene + pembrolizumab combo for BCG-unresponsive NMIBC. Recorded live at Uromigos Live & Unplugged 2023 in Nashville, TN.

Episode 276: ESMO 2023 Highlights 28.10.2023 49:08 ↓

Silke Gillessen joins Tom and Brian to give a summary of the meeting,

Episode 275: Live meeting preview for #UromigosLive 2023 in Nashville 27.10.2023 13:30 ↓

Brian and Tom discuss the benefits and risks of participating in the upcoming meeting . Uncertainty around it’s success are highlighted . Methods of attending remain opaque.

Episode 274: ESMO 2023 STEAP1/BiTE in CRPC shows promise 27.10.2023 19:46 ↓

Kevin Kelly described a Six-transmembrane epithelial antigen of the prostate 1 (STEAP1) bispecific T cell engager showing activity in a phase 1 trial in prostate cancer.

Episode 273: ESMO 2023 - Toripalimab and axitinib in clear cell RCC 26.10.2023 13:47 ↓

Toripalimab plus axitinib as first-line treatment option for advanced RCC by Xinan Sheng

Episode 272: ESMO 2023 - EV302 and CM901 in 1st line bladder cancer 22.10.2023 31:32 ↓

Michiel van der Heijden and Tom discuss EV302 (EVP) and CM901 (chemo/nivo)

Episode 271: ESMO 2023 - THOR: Erdafitinib in bladder cancer 22.10.2023 23:30 ↓

Yohann Loriot described the 2 Thor randomised phase 3 studies

Episode 270: ESMO 2023 - Belzutifan in renal cancer 21.10.2023 28:26 ↓

Lisa Pickering discusses the 2 randomised trial and the 1st line combination study in renal cancer

Episode 269: ESMO 2023 - antibody drug conjugate doublets in UC 21.10.2023 24:52 ↓

Brad McGregor discuses the DAD trial exploring this combo for the 1st time

Episode 268: ESMO 2023 - Enzalutamide and 177Lu-PSMA-617 in CRPC with Louise Emmett 20.10.2023 27:06 ↓

Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)

Episode 267: ESMO preview - things to look out for at the meeting 11.10.2023 27:05 ↓

Silke Gillessen, Brian and Tom look at ESMO 2023 GU track and beyond

Episode 266: Radiotherapy for prostate cancer 10.10.2023 28:45 ↓

Nick James discusses the optimal patients for radiotherapy and his approach to perioperative hormone therapy